 | Up a level |
Journal Article
Ramalingam, S. S., Mazieres, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Baudelet, C., Lestini, B. J. and Rizvi, N. A. (2014). Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys., 90 (5). S. 1266 - 1268. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Reck, M., Vicente, D., Ciuleanu, T., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Wolf, J., Antonia, S. J., Nakagawa, K., Selvaggi, G., Baudelet, C., Chang, H. and Spigel, D. R. (2018). Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Ann. Oncol., 29. S. 43 - 44. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H. and Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann. Oncol., 32 (5). S. 631 - 642. AMSTERDAM: ELSEVIER. ISSN 1569-8041